Piramal Pharma earnings calls.

Piramal Pharma delivered a strong Q1 FY27 with 17% YoY revenue growth to Rs 2,270 croreCurrent reported value: 17% YoY revenue growth to Rs 2,270 crore. No comparable prior figure is available in the source record. and EBITDA expansion of 400bps to 12%Current reported value: EBITDA expansion of 400bps to 12%. No comparable prior figure is available in the source record., translating to 72% EBITDA growth. All three business segments—CDMO (19% growth), Complex Hospital Generics (17% growth), and Consumer Healthcare (mid-teen growth)—contributed uniformly. The CDMO business saw broad-based demand recovery with improved RFP activity directed at higher-margin overseas sites; the Riverview ADC facility is now commercial. Complex Hospital Generics benefited from ex-US market gains and market share expansion in sevoflurane (48%Current 48%. Reported change: Stable. US share). Consumer Healthcare showed robust power brand momentum (23% growth, 53% of sales) and e-commerce acceleration (40% growth, 28% of sales). Management maintained annual guidance while confirming $21 million Q1 capex spend against a $120-135 million full-year budget. Tax rate will remain elevated this year due to overseas facility scaling but normalize to 24-25% by FY30 when targeting 25% EBITDA marginsCurrent reported value: 25% EBITDA margins. No comparable prior figure is available in the source record.. Key risks include Chinese competition in generics, customer decision timeline extensions, and geopolitical tariff uncertainties affecting supply chains.